Slide 1: Investor Presentation August 2026
August 2026 Nasdaq: PBM Investor Presentation
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared by Psyence Biomedical Ltd. ("Psyence BioMed," "PBM," or the "Company") for informational purposes only and not for any other purpose. Neither the Securities and Exchange Commission nor any other securities regulator has passed on the accuracy or adequacy of this p
Slide 3: Mission
To advance a portfolio of nature-derived, evidence-based therapeutics targeting unmet mental health needs in cancer, addiction and related conditions. Mission 02
Slide 4: Strategic Outlook
Strategic Outlook A clinical-stage biotechnology company advancing nature-derived psychedelic therapeutics for mental health, with a focus on palliative care, Alcohol Use Disorder (AUD), Substance Use Disorder (SUD),and longevity science. Psyence BioMed holds a strategic equity stake in PsyLabs, act
Slide 5: Company Highlights
04 Company Highlights Potential regulatory market and data exclusivity for New Medicinal Entities (NME). No debt, a strong cash position, and two strategic, low-cost financing mechanisms in place. Established an ethically sourced and sustainable supply of high-potency iboga bark from trusted sourcin
Slide 6: Anticipated Developmental Pathway to Approval
FDA Pre-IND Feedback Received * Based on currently anticipated study recruitment rate. HREC Approved Phase IIb Study in Adjustment Disorder (Announced March 6, 2024) 05 Southern Star Research (CRO) engaged First Patient Dosed Top Line Results Planned End of Phase II/Type C Meeting with FDA Developme
Slide 7: PBM Development Portfolio
AUD Psilocybin Study Psilocybin 25mg Pre-clinical Phase I Phase II Phase III Milestones Adjustment Disorder Projected Upcoming Top line results H1 2027 In Development In Development PBM Development Portfolio Phase IIb Ibogaine Phase I Program 06 Phase I/II
Slide 8: Phase IIb Clinical Trial
Countries/Sites locations: Target Enrolment: Drug Product / imp: Phase IIb Clinical Trial Psyence BioMed's clinical trial program in Australia using NPX-5 is focused on assessing the safety and efficacy of psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder* associated with a
Slide 9: Prior Proof-of-Concept Studies Provide Encouraging Rationale for Phase IIb
08 At the 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and antidepressant effects – 60-80% of participa
Slide 10: Intellectual Property
Intellectual Property Ownership of all IP and data arising from drug product development and clinical trials sought through: • Establishing data and market exclusivity arising from a successful clinical trial • Filed (through PsyLabs) extensive patent applications on our Investigational Drug Product
Slide 11: Palliative Care – Understanding a growth market
10 Palliative Care is*: • Specialized medical care for people living with a life- limiting illness, such as cancer or heart failure. • It is not end-of-life (Hospice) care. • Patients may continue to receive treatment as well as care intended to manage their symptoms. • Its purpose is to enhance a p
Slide 12: The Global Palliative Care Market is Significant with a Robust Projected CAGR
11 The Global Palliative Care Market is Significant with a Robust Projected CAGR Cancer = ~37% of Total PC Market Projected Global Palliative Care Market $23.3B with 9.1% CAGR (2032)* Cancer $8.6B* Other Disease $14.7B* * Source: https://www.globenewswire.com/news-release/2024/10/15/2963268/0/en/Pal
Slide 13: WHO Study: 56.8 Million People Require Palliative Care
12 WHO Study: 56.8 Million People Require Palliative Care Patients Requiring Palliative Care, Globally (millions) Other Cancer 21.9m 34% of patients requiring palliative care – 19.3 million people – have received a serious cancer diagnosis According to the WHO, "The global need for palliative care w
Slide 14: Recent Academic Studies Provide Encouraging Scientific Rationale
13 Recent Academic Studies Provide Encouraging Scientific Rationale for Continued Development of Psilocybin for SUDs and Patients with Cancer (2024 – 2025)
Slide 15: Adjustment Disorder (AjD)
Adjustment Disorder (AjD) A global survey of psychiatrists by the WHO revealed: • AjD plays an enormous role in healthcare utilization. • AjD ranked 7th among 44 psychiatric categories* they managed at least once a week in their practice. • AjD ranked higher than alcohol use disorder at #8** • A sec
Slide 16: PsyLabs Strategic Alliance
15 • Reliable Supply of Natural Psychedelics: Exclusive partnership with federally licensed PsyLabs secures pharmaceutical-grade psilocybin, ibogaine, DMT, and mescaline – an increasingly rare and valuable asset. • Fully Integrated Biotech Platform: The alliance unifies clinical development, EU-GMP
Slide 17: Emerging Leader in Ibogaine-Based Addiction Therapeutics
16 Emerging Leader in Ibogaine-Based Addiction Therapeutics Psyence BioMed's strategic alliance with PsyLabs is central to its leadership in ibogaine- based addiction therapeutics. Through this partnership, we have secured worldwide rights of first refusal to nature-derived, pharmaceutical-grade ibo
Slide 18: Ibogaine: A Novel Opportunity in Mental Health Treatment
Ibogaine: A Novel Opportunity in Mental Health Treatment A 2024 Stanford study found that a single dose of ibogaine, given to 30 U.S. Special Operations veterans with TBI and PTSD, led to lasting improvements in PTSD, depression, anxiety, and functioning – with no serious side effects. These finding
Slide 19: Psyence BioMed Welcomes U.S. Executive Action on Psychedelics
Psyence BioMed Welcomes U.S. Executive Action on Psychedelics U . S . E X E C U T I V E A C T I O N • President Trump signed an Executive Order on April 18, 2026 to accelerate research and approval of psychedelic-based therapies — including ibogaine — for PTSD, depression and addiction. • $50 millio
Slide 20: Significant Unexplored White Space in Nature Derived Psilocybin & Ibogaine
Significant Unexplored White Space Exists in the Area of Nature Derived Psilocybin & Ibogaine 19
Slide 21: Psyence BioMed Ltd Management Team
20 Psyence BioMed Ltd Management Team Proven Track Record in Innovation with Extensive Pharma Development Experience. Dr. Neil Maresky, Global Head - Clinical Development Trained MD in Emergency Medicine and Family Practice. Former VP Scientific Affairs AstraZeneca Canada Inc. Previously at Wyeth, B
Slide 22: Psyence BioMed Board of Directors
Psyence BioMed Board of Directors Extensive Governance, Operating and Scientific Experience Marc Balkin, Board Member Investor in several successful start-up businesses (Pharma, biotech, chemical processing) Partner at DiGame, Former Partner at Hasso Plattner Ventures, with service on the investment
Slide 23: Contact Us
General inquiries: info@psyencebiomed.com Investor inquiries: ir@psyencebiomed.com Tel: +1-416-477-1708 Address: 121 Richmond Street West Penthouse Suite 1300 Toronto ON M5H 2K1 Canada Contact Us 22